Home / Transcripts / Precipio, Inc. (PRPO) · August 17, 2026

Precipio, Inc. (PRPO) Earnings Call Transcript

August 17, 2026

NASDAQ US Health Care Health Care Providers and Services earnings 19 min

Earnings Call Speaker Segments

Ilan Danieli executive
#1

Good afternoon, everyone, and thanks for being with us on Precipio's shareholder update call for the second quarter of 2026. During today's call, I'll go over our Q2 results, give you some added background on what was behind the quarter, share what we're observing in both our pathology and product businesses, and then cover what to expect as we head into the back half of the year. Once our prepared remarks are done, we'll take your questions. Let me begin by framing this quarter's results. When we spoke three months ago about Q1, we noted that even with revenue that was fairly flat and a modest cash burn, the underlying business, in our view, was still strong; we discussed how the timing of shipments to customers affected the revenue figures for the quarter. We also covered the usual seasonality seen early in the calendar year when it comes to collecting cash. Most importantly, we discussed the commercial pipeline we're building and our expectation that the numbers would show the business keeping up its momentum as the year progresses. I believe our Q2 numbers did precisely that. Quarterly revenues exceeded $7 million for the first time in Precipio's history. We got back to positive adjusted EBITDA. Our operating cash flow came in at about $700,000, and we ended the quarter with more than $3 million on deposit, meaning cash grew by $500,000 over the course of this quarter alone. To me, what stands out most is that this cash position was achieved through our own operations rather than by bringing in outside capital. Looking at Q2, it isn't merely a solid quarter in my view. It represents one more meaningful confirmation of the business model we've invested years in developing. Ahead of walking through the quarterly figures, I want to spend a moment discussing the strategic edge we hold in the marketplace, because in the past we've characterized Precipio as possessing a distinctive flywheel. We have a lab that allows us to identify issues during cancer diagnosis. After that, we build fixes, confirm they work in an actual clinical lab setting, and subsequently commercialize those fixes alongside other labs. Revenue comes from the pathology unit, and at the same time it gives us firsthand visibility into real diagnostic challenges; that represents a meaningful edge over competitors. A way I enjoy describing why this matters is that the typical diagnostic firm builds something first and afterward attempts to duplicate how it would be used inside a clinical lab. They start with a scientific idea, then attempt to translate that idea into a product they assume the market will want. That isn't guaranteed, for a range of reasons — clinical usefulness, workflow, regulation, billing, or economic obstacles can all get in the way. We take another approach. Since we already run a clinical laboratory, what we learn in patient care shapes what we build. We encounter these problems firsthand, develop solutions, and then deploy them inside our own facilities, which improves outcomes for the patient specimens we receive daily, and along the way we demonstrate value clinically, operationally, and financially. Only after all the criteria are met do we begin the effort to take those products outside our own facilities. Those products get made available to other labs, our customers, which means they end up affecting patients well past Precipio's own lab footprint. The lab division is not just a service operation, and the product division is not just a manufacturing operation. Each one strengthens the other, and that is our flywheel. That broadens our addressable market without forcing us to stand up another Precipio laboratory each time we want to reach a new geography or serve another customer. As our product business expands, it generates a more scalable revenue stream next to our core pathology operations. Q2 illustrates our distinctive model well, with both divisions operating in tandem at the same time. Acute myeloid leukemia, or AML, is a really strong illustration of the area where this model delivers the greatest value. Finding diagnostic challenges where we can create a solution that genuinely improves patient care has been our guiding principle from the start. AML fits that perfectly, because the decisions about treatment can be incredibly urgent. The word acute is what the A in AML stands for, and the reality is that these patients confront an immediate danger of death — at times within just 48 hours. In day-to-day practice, though, when molecular lab results that are time-critical take 10 to 14 days on average to arrive, the diagnostics market is failing these patients' clinical needs in a systematic way. The vital data comes back from our rapid AML panel in just 24 hours, so patients begin the correct treatment quickly enough to keep pace with the pressing medical circumstances they confront. Nor is this merely an abstract concept. Every week, multiple patient samples with an AML diagnosis arrive at our lab, and we witness firsthand how delivering those results on the same day satisfies what clinicians require when treating the people in their care. Being able to create and clinically validate solutions within our own lab positions us favorably to launch products addressing genuine clinical challenges that labs and doctors face. Just as crucial, once we'd confirmed those offerings worked in-house, our products division gave us the means to extend their reach past the individuals coming through Precipio's very own lab. That's our mental model for how creativity, benefits to patients, growing an enterprise, and worth returned to shareholders all tie together. This latest stretch, specifically, has drawn a fair amount of attention from a large number of buyers, here at home and abroad alike. On top of genuine revenue, we're working on a number of possible promotional partnerships, plus clinical research efforts meant to shine a light on the issue while positioning our offering right at the center. Layering promotional efforts onto the sales drive is hugely significant in the biotech world. Historically, we lacked the means to fund such programs, yet that is no longer true, and I am eager to walk through a few of them soon. Turning to the figures, let's begin with revenue. Q2 revenue came in above $7 million, versus roughly $6.7 million during Q1. Maybe even more significant, revenue rose about 22% year-over-year, climbing from $5.7 million in the corresponding quarter of 2025. What we have, then, is growth on both a sequential and a year-over-year basis. Looking more closely, our pathology business brought in about $6.1 million, against $6 million in Q1; that gain is modest, though remember, as noted previously, our resources go toward commercial expansion of our products. Actually, our product business brought in about $900,000. That compares with roughly $660,000 during the prior quarter, which works out to a 35% increase. This number is significant. The previous quarterly peak we'd hit for product revenue was around $750,000, and that happened in Q4 of last year — two quarters ago. So Q2 ended up about 21% above that earlier high. Let me quickly connect this to something mentioned on the last call. Back in Q1, we pointed out that a shipment one of our larger customers had expected by the end of March got pushed into early April.

Ilan Danieli executive
#2

At the time, we stressed that this came down to timing rather than losing a customer or any shift in underlying demand. Q2 lets us observe that difference with greater clarity. We all understand on an intuitive level that a company operates as a living, breathing thing, and splitting it into quarters amounts to an arbitrary cutoff, a line drawn in the sand that doesn't necessarily line up with how the business naturally moves. Variability will always arise from quarter-to-quarter timing, especially in our products business. So I think it matters to look past any single quarter and concentrate on the business's positive trajectory. I want to spend a bit of time on products, because to me that's the bigger story this quarter. Yes, there's the 21% increase over our prior record, but what I find equally encouraging is that our pipeline keeps expanding. During Q2, about 10 new distributor reps came on board to work alongside our commercial team. That gives us access to new territories and more prospective buyers; on top of that, we've pinpointed more than 25 newly qualified customers, and we've got over 30 meetings with those new customers that are either on the calendar or already wrapped up in the second quarter. Every one of those things adds further growth to our pipeline. Figuring out the right approach for teaming up with each distributor is something we've flagged as a difficulty in the past. Thermo Fisher Scientific, McKesson, Medline, and Cardinal Health are all partners of ours on the distribution side, and together they cover essentially the entire diagnostics space. A common question from investors has been: "What's behind the slow build of this business?" along with, "What caused a stretch where revenue stayed fairly level?" We've already discussed bringing on a fresh commercial team that kicked off in January of this year — that's a major piece of having capable people who can get out there and sell. On top of that, there's the matter of cultivating those distributor relationships. These four distributors together give us full market reach, and every one of them is a massive company running things its own way. How their sales teams are organized isn't the same, they engage with vendors using different methods, and the way they're motivated shifts from company to company. You can't apply one approach everywhere. Credit goes to our commercial group, who are getting better at cracking those distinct formulas for each distributor, and we're seeing the payoff in a sizable lift to our pipeline. Once we're into the back half of the year, my expectation is that we'll begin shifting those accounts out of pipeline into active status, with the revenue that follows adding meaningfully to our growth. Now for pathology. Sales came in at about $6.1 million, up from $6 million in Q1. That's a small gain quarter over quarter, but keep in mind what this unit is for — we've called it before a vital piece of Precipio's flywheel. What we're after is repeat business plus cash generation, and what matters even more is that it gives us the clinical backbone underlying our product development. So our thinking is that this unit will continue to grow on its own while still doing its job for the wider company. Moving over to profitability, adjusted EBITDA came in at roughly $400,000 during Q2 versus — $200,000 in Q1; that works out to a swing of about $600,000 between the two quarters. Two main factors drove that shift. To start with, revenue rose by around $300,000, and next, stock-based compensation expense fell by roughly $200,000. In my view the bigger picture matters more than whatever single expense line happens to be. When revenue climbs, we get the chance to leverage infrastructure that's already in place. Q2 offers yet another illustration of that operating leverage. There's a real distinction between purchasing growth through heavy spending versus scaling up on top of infrastructure that's already been built. We've put in years constructing the laboratory, creating our products, setting up the commercial infrastructure, and getting people and systems established. As revenue expands on that platform, we anticipate a greater share of each incremental dollar flowing down into the P&L. Which leads me to what may be the single most significant figure in this quarter's results, cash. We produced about $700,000 of cash from operations in Q2, equal to 10% of the quarterly top-line figure; that's a notable accomplishment, especially given our modest revenue figures and our size. Total cash rose by roughly $500,000 dollars, and as Q2 closed, we hold $3 million cash in the bank. To give you a sense of the contrast, at the close of Q2 a year ago, we held roughly $1.1 million in cash. One point I want to emphasize: this improvement did not come from any financing activity — it came from our business operations, and for a company at our stage in our industry, that difference really matters. Companies in the emerging growth phase, particularly in diagnostics and biotech, typically find themselves returning to the capital markets again and again to finance their expansion. We've taken a different path. We've put in serious effort to create a business capable of covering a growing share of its own growth through internal operations. Generating $700,000 in operating cash even while growing the business says a lot about what this model could produce as we continue scaling. Now, looking ahead to the back half of 2026, what should shareholders keep an eye on as we move into that period? To start, we anticipate that revenue growth will carry on. We've passed the $7 million mark on a quarterly basis at this point. From here, our emphasis is on building. Next, growth in products revenue. Reaching about $900,000 in quarterly product revenue represents a major milestone, and we're still working to broaden both the customer base and the commercial reach of that business. Third, conversion of the commercial pipeline. We have put money into growing our sales team, and that spending will keep going, because we believe the pipeline those efforts create will show up more and more as revenue. Number four is operating leverage. As sales climb, we'll remain focused on converting that growth into adjusted EBITDA and ultimately into cash generation. Let me wrap up here. Three months back, we asked investors to look beyond a Q1 that came in roughly flat and to focus instead on what sat beneath the headline numbers. Q2 is why. Revenue in the quarter — especially product revenue — reached a record high for the company, and the business delivered strong adjusted EBITDA along with cash flow. This is a major set of financial achievements, and they come from a business and commercial engine that's running well. We're not viewing this as the endpoint. What it shows us is evidence that the framework we put in place is beginning to deliver the operating leverage and the ability to generate cash that we've been working toward. Now our focus is execution; we have to continue building and turning the commercial product pipeline into results. We have to keep innovating and bringing forward new products that can improve patient care and give our customers more value; we have to demonstrate that revenue growth keeps flowing through to EBITDA and cash flow, which ultimately drives shareholder value. My sense is that we're heading into the second half of 2026 from a stronger position than at any point before, and the opportunities in front of us have us excited. Thanks once more for your ongoing support and for being with us today.

Ilan Danieli executive
#3

With that, we'll open the call to questions.

Adam Hutt analyst
#4

Hey, everyone. Nice work on a strong quarter.

Ilan Danieli executive
#5

I've got a question — Ilan Danieli: Thanks.

Adam Hutt analyst
#6

Is there anything you can tell us about that strange surge in volume last month, when roughly 800,000 shares changed hands across a two-day stretch? What was the source of those shares? How did that even happen? Do you have any handle on it whatsoever?

Ilan Danieli executive
#7

Yes. Hi, Adam. Appreciate the question. Truthfully, I'd like it if we could provide greater visibility on our side regarding that. With a Bloomberg Terminal, you likely have a better view than we do, so this caught me off guard just as much as it did you. My sense is that we're beginning to reap the benefits of certain IR efforts we've undertaken, such as taking part in investing conferences. We put on a terrific event at the Planet MicroCap Conference in Vegas back in, when did that happen? June, I believe. So I think the word is getting out, exactly as we anticipated following our emergence at the start of the year. I think we're drawing an increasing amount of notice. The other element, naturally, as you're aware, is computerized algo trading, which is extremely difficult to follow and extremely difficult to account for.

Adam Hutt analyst
#8

Certainly. Very well. Thanks, everyone.

Ilan Danieli executive
#9

Yes. Thanks.

Ilan Danieli executive
#10

Alright, I simply wanted to express gratitude to each of you for being here and for the backing you keep giving. Enjoy a pleasant evening, all of you. Thanks.

Operator operator
#11

This concludes today's call. Thank you for participating. You may all disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Precipio, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Precipio, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.